Jim joined Sofinnova in 2000 as a General Partner. He focuses on funding clinical stage private and publicly traded bio-pharmaceutical companies. He has financed or served on the board of ten companies which received drug approvals from either FDA or EMA, seventeen companies which completed initial public offerings, and eleven companies which were acquired as private or as public companies. Jim currently represents Sofinnova on the board of directors of Ascendis (ASND), Coherus (CHRS), Edge (EDGE), Natera (NTRA), Obseva (OBSV), Nucana (NCNA), Iterum and Y-mAbs.
Prior to Sofinnova, Jim worked at Bayer (Miles) and Sanderling. In 2011, Jim won the IBF Risk Innovator Award and was named as one of the industry’s top Life Science investors in 2013 by Forbes Magazine. Jim has authored or co-authored thirteen peer reviewed articles and invited reviews, including three papers published in Nature. Jim received his MD and PhD in Immunology from Stanford University. At Stanford, he was a Beckman Scholar, received a Novartis Bursary Award and was funded by the NIH Medical Scientist Training Program.
Jim graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors and received a Departmental Citation. Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California Berkeley and has lectured on entrepreneurship at Stanford University. Jim formerly served as a Director on the Board of the National Venture Capital Association (NVCA) and on the Board of the Biotechnology Industry Organization (BIO).